Colgate-Palmolive Company
CL
$93.21
+1.05%
Colgate-Palmolive is a global leader in household and personal care products, best known for its oral care line (over 40% of sales) and also manufactures shampoos, shower gels, deodorants, and home care items sold in over 200 countries, with a significant pet nutrition segment through Hill's. As a dominant player in the consumer defensive space, the company benefits from strong brand loyalty and extensive international distribution, particularly in emerging markets which account for nearly half of sales. The current investor narrative centers on the company's ability to sustain growth amid a rotation toward value and defensive stocks, with recent attention on margin resilience and the performance of its Hill's pet food business, which contributes nearly one-fourth of total revenue.…
CL
Colgate-Palmolive Company
$93.21
Investment Opinion: Should I buy CL Today?
Rating: Hold. Colgate-Palmolive is a high-quality defensive name, but its current valuation leaves limited upside. The analyst consensus is Buy with an average target of ~$108.80, implying 18% upside, but the trailing P/E of 29.93x is near historical highs, suggesting much of the good news is already priced in.
Supporting Evidence: The company boasts a gross margin of 60.15%, TTM free cash flow of $3.63 billion, and a dividend yield of 2.85%. Revenue grew 5.78% YoY in Q4 2025, and the forward P/E of 22.76x implies expected earnings growth. However, the PEG ratio is negative (-1.19) due to negative earnings growth in the TTM, indicating that growth expectations may be optimistic. The stock trades at a P/S of 3.14x, below the industry EV/Sales of 3.84x, offering some value on a sales basis.
Risks & Conditions: The biggest risks are valuation compression if the P/E contracts to 22x (sector average), and revenue growth deceleration below 3%. This Hold would upgrade to Buy if the stock pulls back to $80 (P/E ~25x) or if revenue growth accelerates above 7%. It would downgrade to Sell if the company reports two consecutive quarters of revenue growth below 3% or if gross margins fall below 58%. Overall, the stock appears fairly valued to slightly overvalued relative to its history and peers, given the premium P/E.
Sign up to view all
CL 12-Month Price Forecast
Colgate-Palmolive offers a compelling defensive profile with strong margins and cash flow, but its valuation is stretched relative to history and peers. The base case of modest growth and stable multiples suggests limited upside from current levels, while the bear case of multiple contraction poses a real risk. The neutral stance reflects the balanced risk/reward: the stock is a solid hold for income-oriented investors, but not a compelling buy for growth seekers. An upgrade to bullish would require evidence of accelerating revenue growth or a pullback to a more attractive entry point.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $121.17 and implied upside of +30.0% versus the current price.
Average Target
$121.17
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$75 - $121
Analyst target range
Colgate-Palmolive is covered by 6 analysts, with a consensus leaning bullish: 4 Buy/Overweight ratings, 2 Hold/Equal Weight, and no Sell ratings. The average target price is not explicitly provided, but based on the estimated EPS of $4.78 and a forward P/E of 22.76x, the implied target is approximately $108.80, suggesting 18% upside from the current price of $92.24. The consensus recommendation is a Buy, reflecting confidence in the company's defensive qualities and growth prospects. The target range from low to high is $4.66 to $4.87 on EPS, implying a price range of $106 to $111 based on the forward P/E. The high target assumes continued margin expansion and strong pet nutrition growth, while the low target factors in potential input cost inflation or slower emerging market demand. Recent ratings actions include an upgrade from Deutsche Bank to Buy in March 2026, while Barclays and Wells Fargo maintain Equal Weight, indicating mixed but generally positive sentiment. The narrow EPS range suggests relatively high conviction among analysts.
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a mixed picture: its strong brand portfolio, high gross margins, and consistent free cash flow provide a solid defensive foundation, while the low beta and recent analyst upgrades support a bullish case. However, the elevated trailing P/E near historical highs, Q4 net loss, and decelerating revenue growth introduce significant risks. The bull case currently has slightly stronger evidence due to the company's proven ability to generate cash and maintain margins, but the key tension is whether the premium valuation can be sustained if growth continues to decelerate. The single most important factor is the trajectory of organic revenue growth—if it accelerates above 5%, the stock could re-rate higher; if it falls below 3%, multiple compression could lead to a 15-20% downside.
Bullish
- Strong Brand Portfolio and Global Reach: Colgate-Palmolive operates in over 200 countries with leading brands in oral care (over 40% of sales) and pet nutrition (Hill's, ~25% of sales). International sales account for about 70% of total revenue, with nearly half from emerging markets, providing diversification and growth opportunities.
- Resilient Gross Margin Above 60%: Gross margin remained stable at 60.15% in Q4 2025 versus 60.36% a year ago, demonstrating pricing power and cost control despite inflationary pressures. This high margin is a key competitive advantage in the household products industry.
- Consistent Free Cash Flow Generation: TTM free cash flow is $3.63 billion, supporting a dividend yield of 2.85% and $406 million in share repurchases in Q4 2025 alone. This cash generation provides a cushion for reinvestment and shareholder returns.
- Low Beta and Defensive Appeal: With a beta of 0.319, the stock is significantly less volatile than the market, making it attractive during periods of uncertainty. Recent rotation toward defensive stocks has supported the stock's 9.37% gain over the past three months.
Bearish
- Elevated Trailing P/E Near Historical High: The trailing P/E of 29.93x is at the upper end of its 5-year range (20x-30x) and represents a 36% premium to the consumer defensive average of ~22x. This leaves little room for error, and any earnings miss could trigger multiple contraction.
- Q4 2025 Net Loss and Earnings Volatility: The company reported a net loss of -$37 million in Q4 2025, swinging from a $739 million profit in Q4 2024, due to a $970 million other expense. This highlights the potential for one-time charges to significantly impact earnings.
- Revenue Growth Deceleration: Quarterly revenue has shown a decelerating trend: Q1 2025 $4.91B, Q2 $5.11B, Q3 $5.13B, Q4 $5.23B. The 5.78% YoY growth in Q4 is modest and may slow further if emerging market demand weakens or competition intensifies.
- High Debt-to-Equity Ratio: Debt-to-equity stands at 147.93%, which is elevated for a consumer defensive company. While manageable given strong cash flows, it increases financial risk if interest rates remain high or if cash flow deteriorates.
CL Technical Analysis
Colgate-Palmolive is in a sustained uptrend, with the stock up 1.79% over the past year and currently trading at $92.24, which is 92.8% of its 52-week range (high $99.33, low $74.55). This positioning near the upper end of the range suggests strong momentum and investor confidence, though it also implies the stock may be pricing in optimistic expectations. The 1-year price change of 1.79% underperforms the S&P 500's 20.63% gain, indicating relative weakness but also a defensive rotation appeal. Short-term momentum is accelerating, with the stock gaining 2.55% in the past month and 9.37% over the past three months, outpacing the S&P 500's 4.07% and 11.11% gains respectively. The 1-month relative strength of -1.52% versus the S&P suggests a slight lag, but the 3-month relative strength of -1.74% indicates the stock is keeping pace. The divergence between the strong 3-month trend and the weaker 1-year trend may signal a recent shift in investor sentiment toward defensive names. Key support lies at the 52-week low of $74.55, while resistance is at the 52-week high of $99.33. A breakout above $99.33 would signal a new uptrend leg, while a breakdown below $74.55 could indicate a reversal. With a beta of 0.319, the stock is significantly less volatile than the market, making it a lower-risk holding suitable for conservative portfolios.
Beta
0.32
0.32x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+4.1%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +4.2% | +1.0% |
| 3m | +10.8% | +7.9% |
| 6m | +10.2% | +8.5% |
| 1y | +4.1% | +20.1% |
| ytd | +20.0% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth has been steady, with the most recent quarter (Q4 2025) reporting $5.23 billion, up 5.78% year-over-year from $4.94 billion in Q4 2024. However, the multi-quarter trend shows deceleration: Q1 2025 revenue was $4.91 billion, Q2 $5.11 billion, Q3 $5.13 billion, and Q4 $5.23 billion, indicating a slowing growth trajectory. The oral, personal, and home care segment generated $4.03 billion in the latest quarter, while pet nutrition contributed $1.20 billion, with the latter being a key growth driver. The company reported a net loss of -$37 million in Q4 2025, swinging from a net income of $739 million in Q4 2024, primarily due to a $970 million other expense. Gross margin remains healthy at 60.15% in Q4 2025, relatively stable compared to 60.36% in Q4 2024, indicating pricing power and cost control. Operating margin was 20.59% in Q4 2025, down from 22.05% in Q4 2024, but still robust for the household products industry. The company maintains a strong balance sheet with a debt-to-equity ratio of 147.93%, which is elevated but manageable given its consistent free cash flow generation of $3.63 billion TTM. Free cash flow per share is $1.59, and the company returned $523 million in dividends and $406 million in share repurchases in Q4 2025, demonstrating a commitment to shareholder returns. ROE stands at 39.48%, reflecting efficient use of equity, though the current ratio of 0.995 indicates tight liquidity.
Quarterly Revenue
$5.2B
2025-12
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
60.2%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Since net income is positive on a TTM basis (despite the Q4 loss), the trailing P/E ratio of 29.93x is the primary valuation metric. The forward P/E of 22.76x implies the market expects earnings growth, with the gap between trailing and forward suggesting a 24% earnings increase anticipated. The stock trades at a P/S ratio of 3.14x, which is below the industry average of 3.84x (EV/Sales), indicating a slight discount on a sales basis. Compared to the sector, the trailing P/E of 29.93x is above the consumer defensive average of around 22x, representing a 36% premium, likely justified by Colgate's strong brand portfolio and global reach. Historically, the stock's P/E has ranged from 20x to 30x over the past five years, with the current 29.93x near the upper end of that band. This suggests the market is pricing in optimistic growth expectations, and any earnings miss could lead to multiple contraction. The P/B ratio of 1,183x is extreme due to negative equity in some periods, making it less meaningful.
PE
29.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -430x~3280x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate-Palmolive's debt-to-equity ratio of 147.93% is high for a consumer defensive company, though it is supported by TTM free cash flow of $3.63 billion. The Q4 2025 net loss of -$37 million, driven by a $970 million other expense, underscores earnings volatility from one-time items. The current ratio of 0.995 indicates tight liquidity, which could become problematic if cash flow weakens. Additionally, revenue growth is decelerating, with Q4 2025 growth of 5.78% YoY, down from prior quarters, suggesting potential market saturation or competitive pressure.
Market & Competitive Risks: The stock's trailing P/E of 29.93x is at the high end of its historical range and represents a 36% premium to the consumer defensive sector average of ~22x, making it vulnerable to valuation compression if investor sentiment shifts away from defensive stocks. With a beta of 0.319, the stock is less correlated to the market, but a rotation back to growth stocks could reduce demand. Recent news highlights a rotation trade favoring defensive names, which has supported the stock, but any reversal could lead to underperformance. Competitive threats from private labels and other global players in oral care and pet food could pressure market share.
Worst-Case Scenario: In a severe downturn, a combination of slowing revenue growth (below 3%), margin compression from input cost inflation, and a de-rating of the P/E multiple to 22x (sector average) could drive the stock down to the 52-week low of $74.55, representing a potential loss of approximately 19% from the current price of $92.24. This scenario would likely require a prolonged period of weak earnings and negative analyst revisions.
FAQ
The primary risk is valuation compression: if the P/E contracts from 29.93x to the sector average of 22x, the stock could fall ~25%. Financial risks include a high debt-to-equity ratio of 147.93% and a current ratio below 1, which could strain liquidity. Competitive risks from private labels and other global brands could pressure market share and margins. Additionally, the Q4 2025 net loss of -$37 million highlights earnings volatility from one-time items. The most severe risk is a prolonged slowdown in emerging markets, which account for nearly half of sales.
The 12-month outlook is balanced: the base case (50% probability) sees the stock trading between $95 and $105, driven by modest revenue growth of 4-5% and a stable P/E. The bull case (25% probability) targets $105-115, assuming accelerated growth and multiple expansion. The bear case (25% probability) sees the stock falling to $75-85 if growth disappoints and the P/E contracts. Analyst consensus is Buy with an average target of ~$108.80, implying 18% upside. The most likely scenario is the base case, with the stock hovering near current levels.
Based on a trailing P/E of 29.93x, CL appears overvalued relative to the consumer defensive sector average of 22x, representing a 36% premium. However, the forward P/E of 22.76x suggests the market expects earnings growth, which could justify the premium if realized. The P/S ratio of 3.14x is below the industry EV/Sales of 3.84x, indicating some value on a sales basis. Historically, the stock has traded between 20x and 30x P/E, so the current level is near the high end. Overall, the stock is fairly valued to slightly overvalued, with the premium reflecting its defensive qualities and brand strength.
Colgate-Palmolive is a high-quality defensive stock with a strong brand, stable margins, and consistent cash flow, but its current valuation is elevated. The trailing P/E of 29.93x is near the top of its historical range and well above the sector average of 22x, limiting near-term upside. Analysts see 18% upside to an average target of ~$108.80, but this depends on sustained growth. For long-term, income-focused investors, CL is a reasonable hold, but for growth-oriented investors, the risk/reward is less attractive at current levels. A better entry point would be below $85, where the P/E would be closer to 25x.
CL is best suited for long-term, income-oriented investors due to its low beta (0.319), stable dividend yield of 2.85%, and defensive business model. Short-term traders may find limited volatility, as the stock's low beta reduces the potential for quick gains. The company's consistent free cash flow and strong brand support a long-term holding period of at least 3-5 years. However, the current premium valuation suggests that short-term upside is capped, making it less ideal for tactical trades. A minimum holding period of 3 years is recommended to ride out valuation fluctuations.